Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China

BACKGROUND: There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC. METHODS: The medical records of patients who received sequential...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Zihua, Hao, Xuezhi, Zhang, Cuiying, Li, Haojing, Dong, Guilan, Peng, Yumei, Ma, Kewei, Guo, Ye, Shan, Li, Zhang, Yan, Liang, Li, Gu, Yangchun, Xing, Puyuan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720624/
https://www.ncbi.nlm.nih.gov/pubmed/34851035
http://dx.doi.org/10.1111/1759-7714.14232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720624/
https://www.ncbi.nlm.nih.gov/pubmed/34851035
http://dx.doi.org/10.1111/1759-7714.14232

Ejemplares similares